Goldman Sweetens Terms on Loan for DuPont Unit Sale

Financing for Arclin's acquisition of DuPont's Aramids business faces ongoing struggles in leveraged loan market.

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Goldman Sachs Group Inc. has further sweetened the terms on a $1.25 billion financing package tied to chemical maker Arclin Inc.'s acquisition of DuPont de Nemours Inc.'s Aramids business. The term loan B is now being offered at a discounted price of 92 cents on the dollar, down from the previously reduced level of 93-94 cents. The deadline for lender commitments has also been extended to Wednesday.

Why it matters

The ongoing struggles in the leveraged loan market have forced Goldman to make additional concessions to attract lenders for this financing package. This highlights the challenges facing companies seeking debt financing for mergers and acquisitions amid tightening credit conditions.

The details

The $1.25 billion term loan B financing is part of the package supporting Arclin's acquisition of DuPont's Aramids business. Goldman has had to sweeten the terms further, offering the loan at 92 cents on the dollar, down from the previously reduced level of 93-94 cents. The deadline for lender commitments has also been extended to Wednesday, indicating ongoing difficulties in securing the necessary financing.

  • The initial lender commitment deadline was February 27.
  • The new deadline is 3 p.m. in New York on Wednesday, March 6.

The players

Goldman Sachs Group Inc.

A global investment banking and securities firm that is providing the $1.25 billion financing package for Arclin's acquisition of DuPont's Aramids business.

Arclin Inc.

A chemical maker that is acquiring DuPont's Aramids business.

DuPont de Nemours Inc.

A chemical company that is selling its Aramids business to Arclin.

Got photos? Submit your photos here. ›

What’s next

The judge will decide on Wednesday whether to approve the final terms of the $1.25 billion financing package.

The takeaway

The ongoing challenges in the leveraged loan market are forcing Goldman to make significant concessions to secure financing for this acquisition, underscoring the broader tightening of credit conditions that companies are facing.